Pelgran Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 29-07-2024
- Paid Up Capital ₹ 1.59 Cr
as on 29-07-2024
- Company Age 11 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.24 Cr
as on 29-07-2024
- Revenue -37.10%
(FY 2023)
- Profit -55.71%
(FY 2023)
- Ebitda -313.78%
(FY 2023)
- Net Worth -281.01%
(FY 2023)
- Total Assets -3.71%
(FY 2023)
About Pelgran Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.59 Cr.
The company currently has active open charges totaling ₹3.24 Cr.
Rajesh Alla, Bharatha Vadlamudi, Pavani Undavalli, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24232TG2013PTC088354
- Company No.
088354
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Jun 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Pelgran Pharma?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Alla  | Director | 12-Jun-2013 | Current |
| Bharatha Vadlamudi | Director | 08-Jun-2020 | Current |
| Pavani Undavalli | Director | 12-Jun-2013 | Current |
| Purnima Alla | Director | 12-Jun-2013 | Current |
| Laxminarayana Darakapalli | Director | 01-Apr-2019 | Current |
Financial Performance of Pelgran Pharma.
Pelgran Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 37.1% decrease. The company also saw a substantial fall in profitability, with a 55.71% decrease in profit. The company's net worth observed a substantial decline by a decrease of 281.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pelgran Pharma?
In 2023, Pelgran Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Cary - Air Systems Private LimitedActive 32 years 9 monthsBharatha Vadlamudi, Pavani Undavalli and 1 more are mutual person
Ankit Cooling Systems Private LimitedActive 19 years 8 monthsBharatha Vadlamudi and Purnima Alla are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Andhra Bank Creation Date: 05 Nov 2014 | ₹3.24 Cr | Open |
How Many Employees Work at Pelgran Pharma?
Unlock and access historical data on people associated with Pelgran Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pelgran Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pelgran Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
